Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$545.11 +0.5%	$579.54	$429.27 ▼ $678.21	$33.28B	0.37	329,322 shs	517,680 shs
BIIB Biogen	$133.19 +2.4%	$126.09	$110.04 ▼ $238.00	$19.52B	0.14	1.43 million shs	1.47 million shs
BNTX BioNTech	$108.26 +0.7%	$102.94	$76.53 ▼ $131.49	$26.02B	1.29	940,523 shs	998,480 shs
QGEN Qiagen	$48.59 +0.8%	$44.47	$37.63 ▼ $49.30	$10.80B	0.68	1.19 million shs	1.47 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-1.59%	-4.50%	-5.94%	-7.05%	+24.93%
BIIB Biogen	+3.57%	+2.98%	-0.79%	-0.95%	-43.88%
BNTX BioNTech	+0.98%	+2.30%	+12.33%	+15.21%	+36.38%
QGEN Qiagen	+0.25%	+2.02%	+6.78%	+20.29%	+23.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.3047 of 5 stars	4.5	3.0	0.0	0.0	2.5	1.7	2.5
BIIB Biogen	4.9602 of 5 stars	4.2	5.0	0.0	3.7	3.3	1.7	2.5
BNTX BioNTech	2.4867 of 5 stars	4.4	2.0	0.0	0.0	1.8	0.8	0.0
QGEN Qiagen	3.7647 of 5 stars	1.2	5.0	0.8	4.5	2.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.05	Buy	$729.93	33.91% Upside
BIIB Biogen	2.38	Hold	$188.48	41.51% Upside
BNTX BioNTech	2.83	Moderate Buy	$137.86	27.34% Upside
QGEN Qiagen	2.30	Hold	$49.40	1.67% Upside

Current Analyst Ratings Breakdown

Latest QGEN, BIIB, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/26/2025	QGEN Qiagen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/24/2025	QGEN Qiagen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	14.78	$2.94 per share	185.57	$90.49 per share	6.02
BIIB Biogen	$9.68B	2.02	$24.53 per share	5.43	$114.71 per share	1.16
BNTX BioNTech	$2.98B	8.74	N/A	N/A	$87.61 per share	1.24
QGEN Qiagen	$2.00B	5.39	$3.24 per share	14.99	$16.05 per share	3.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	33.63	50.24	1.00	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	13.15	8.07	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
QGEN Qiagen	$83.59M	$0.40	121.83	19.75	2.45	4.68%	14.61%	8.80%	7/30/2025 (Estimated)

Latest QGEN, BIIB, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	QGEN Qiagen	$0.60	N/A	N/A	N/A	$523.97 million	N/A
7/24/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/7/2025	Q1 2025	QGEN Qiagen	$0.50	$0.55	+$0.05	$0.41	$465.66 million	$483.46 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	$0.25	0.51%	N/A	62.50%	N/A

Latest QGEN, BIIB, ARGX, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN Qiagen		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BIIB Biogen	0.27	1.44	1.01
BNTX BioNTech	0.01	10.18	10.02
QGEN Qiagen	0.40	3.37	2.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
QGEN Qiagen	70.00%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BIIB Biogen	0.18%
BNTX BioNTech	19.20%
QGEN Qiagen	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
QGEN Qiagen	5,765	222.29 million	202.29 million	Optionable

QGEN, BIIB, ARGX, and BNTX Headlines

Recent News About These Companies

Qiagen N.V. (NYSE:QGEN) Declares Dividend of $0.25

July 1 at 7:45 AM | marketbeat.com

Allspring Global Investments Holdings LLC Raises Holdings in QIAGEN N.V. (NYSE:QGEN)

June 29 at 5:32 AM | marketbeat.com

Bank of America Forecasts Strong Price Appreciation for QIAGEN (NYSE:QGEN) Stock

June 28, 2025 | americanbankingnews.com

Qiagen Partnership Program Aims to Build out Clinical dPCR Menu

June 27, 2025 | 360dx.com3

Qiagen N.V. (QGEN) Stock Price, Quote, News & Analysis - Seeking Alpha

June 27, 2025 | seekingalpha.com

Canvas Wealth Advisors LLC Trims Position in Qiagen N.V. (NYSE:QGEN)

June 27, 2025 | marketbeat.com

Here's Why Qiagen (QGEN) is a Strong Value Stock - Nasdaq

June 26, 2025 | nasdaq.com

Qiagen (NYSE:QGEN) Price Target Raised to $53.00 at Bank of America

June 26, 2025 | marketbeat.com

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

June 26, 2025 | businesswire.com

Barclays Initiates Coverage of Qiagen N.V. (QGEN) with Overweight Recommendation

June 25, 2025 | msn.com

Bank of Italy Has $31.72 Million Stock Position in Qiagen N.V. (NYSE:QGEN)

June 25, 2025 | marketbeat.com

Qiagen (NYSE:QGEN) Coverage Initiated by Analysts at Barclays

June 25, 2025 | americanbankingnews.com

Barclay's Initiates Coverage of Qiagen With Overweight Rating

June 24, 2025 | 360dx.com3

QGEN vs. EXAS: Which Stock Is the Better Value Option?

June 24, 2025 | zacks.com

Here's Why Qiagen (QGEN) is a Strong Value Stock

June 24, 2025 | zacks.com

Qiagen (NYSE:QGEN) Now Covered by Analysts at Barclays

June 24, 2025 | marketbeat.com

Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy?

June 23, 2025 | zacks.com

Here's Why Qiagen (QGEN) is a Strong Growth Stock

June 20, 2025 | zacks.com

Qiagen Inaugurates dPCR Partnering Program With Gencurix Oncology Agreement

June 19, 2025 | 360dx.com3

QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock

June 19, 2025 | zacks.com

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18, 2025 | dutchnews.nlD

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN, BIIB, ARGX, and BNTX Company Descriptions

argenex NASDAQ:ARGX

$545.11 +2.64 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$545.11 0.00 (0.00%)

As of 04:42 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Biogen NASDAQ:BIIB

$133.19 +3.12 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$133.61 +0.42 (+0.32%)

As of 05:16 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$108.26 +0.75 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$108.38 +0.11 (+0.11%)

As of 05:19 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Qiagen NYSE:QGEN

$48.59 +0.38 (+0.79%)

Closing price 03:59 PM Eastern

Extended Trading

$48.62 +0.03 (+0.07%)

As of 04:21 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time